By Julia Karow

Stakeholders of VisiGen Biotechnologies, a Houston-based company developing a single-molecule DNA sequencing technology that was acquired by Life Technologies' predecessor Invitrogen in 2008, have lost in arbitration of a breach-of-contract and fraud suit they brought against Life Tech two years ago.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.